BioNTech is shelling out $800 million upfront to acquire China-based Biotheus in a move that would give it access to a ...
BioNTech SE (BNTX) has released an update. BioNTech SE is set to acquire Biotheus in a deal valued at $800 million, aiming to strengthen its ...
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...
Im Kampf gegen Krebs wagt Biontech die größte Transaktion der Firmengeschichte. Die Übernahme von Biotheus ist für die ...
Biontech erweitert seine Pipeline an Krebsmedikamenten mit einem bis zu knapp eine Milliarde Dollar schweren Zukauf. Für die ...
BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...
DPA International on MSN9h
Germany's BioNTech to buy Chinese firm with promising cancer drugGermany pharmaceutical company BioNTech, which shot to global prominence after its early coronavirus vaccine, has boosted its ...
German drugmaker to use state-of-art antibody in tandem with advanced therapies to more effectively fight cancer, detect ...
Das Mainzer Pharmaunternehmen BioNTech übernimmt das chinesische Biotechnologie-Unternehmen Biotheus. BioNTech erweitert ...
BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...
Die Mainzer zahlen einen hohen dreistelligen Millionenbetrag für die Firma Biotheus. Damit verbunden sind Rechte an einem ...
Das Mainzer Pharmaunternehmen BioNTech übernimmt das chinesische Biotechnologie-Unternehmen Biotheus. BioNTech erweitert ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback